3.30

11.41% -0.425

After Hours: 3.32 0.02 +0.61%

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $3.30, with a volume of 268.64K. It is down -11.41% in the last 24 hours and down -48.74% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$3.725

Open:

$3.73

24h Volume:

268.64K

Relative Volume:

2.52

Market Cap:

$30.88M

Revenue:

Net Income/Loss:

$-16.76M

P/E Ratio:

-41.25

EPS:

-0.08

Net Cash Flow:

$-132.97M

1W Performance:

-38.14%

1M Performance:

-48.74%

6M Performance:

-80.22%

1Y Performance:

-90.43%

1-Day Range:

$3.1601

$3.75

1-Week Range:

$3.1601

$5.50

52-Week Range:

$3.1601

$36.00

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1176)

Industry

Biotechnology (676)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

143

Twitter

@x4pharma

Next Earnings Date

2025-03-25

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	3.30	30.88M	0	-16.76M	-132.97M	-0.08
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

May 04, 2025

HC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $7.00 - Defense World

May 04, 2025

May 02, 2025

Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow

May 02, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView

May 02, 2025

X4 Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025

XFOR: HC Wainwright Raises Price Target for X4 Pharmaceuticals | - GuruFocus

May 02, 2025

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - Quantisnow

May 02, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025